|
|
|
| PES1 Interacts with Estrogen Receptor |
| LI Jie-ping1, ZHUANG Qin-ren1, LAN Xiao-peng2, ZENG Guo-bin1, LUO Xiao-feng 1 |
1. Department of Clinical Medical Laboratory, General Hospital of Fujian Corps of CAPF, Fuzhou 350003, China;
2. Institute of Clinic Lab Medicine, Fuzhou General Hospital of Nanjing Military Command, PLA, Fuzhou 350003, China |
|
|
|
Abstract Estrogen(E2) and estrogen receptors (ER) play a vital role in the E2-induced neoplasms. The coregulators of ERs modulate their biological functions by binding these receptor. PES1, as a potential regulator, is mainly expressed in the target organs such as breast and ovarian, and also, is highly expressed in the breast cancer cells. In current work, the HA-tagged recombinant plasmids of full-length PES1, and its different function regions(1~322aa, 312~588aa and 414~588aa) were constructed by PCR. To test whether PES1 can interact with ERs and their interaction regions, different recombinant plasmids constructed were co-transfected with FLAG-ERα or/and FLAGC-ERβ in 293T cells before co-immunoPrecipitation (co-IP). The co-IP results showed that PES1 could interact with ERα and ERβ by binding their 1~322aa region. Further experiments demonstrated that PES1 specifically inhibited the transactivation activity of ERβ in E2-independent manner by analyzing estrogen receptor element luciferase (ERE-LUC). These results suggested that PES1 may act as a new ER coregulator. Further mechanisms and roles in the ERβ signaling pathway and E2-induced neoplasms remain to be determined.
|
|
Received: 09 April 2012
Published: 25 August 2012
|
|
|
|
|
[1] 张浩, 李杰萍, 王晓辉, 等. Pescadillo抗体的制备及其表达研究. 中国科学(C辑:生命科学), 2007, 37(2): 135-142. Zhang H, Li J P, Wang X H, et al. The antibody preparation and expression of human Pescadillo. Sci China C Life Sci, 2007, 37(2):135-142.
[2] 李杰萍, 庄庆仁, 兰小鹏, 等. 制备单克隆抗体检测PES1的表达. 细胞与分子免疫学杂志. 2012, 28(2): 174-176. Li J P, Zhuang Q R, Lan X P, et al. Detect the PES1 expression with prepared monoclonal antibody. Chin J Cell Mol Immunol, 2012, 28(2): 174-176.
[3] Li J, Yu L, Zhang H, et al. Down-regulation of pescadillo inhibits proliferation and tumorigenicity of breast cancer cells. Cancer Sci, 2009, 100(12): 2255-2260.
[4] 李杰萍, 熊志红, 杨智洪, 等. 雌激素受体α转录激活系统的构建. 中华妇产科杂志, 2008, 43(8):611-614. Li J P, Xiong Z H, Yang Z H, et al. Establishment of estrogen receptor alpha transactivation system. Chin J Obstet Gynecol, 2008, 43(8): 611-614.
[5] Li Y F, Hu W, Fu S Q, et al. Aromatase inhibitors in ovarian cancer: is there a role? Int J Gynecol Cancer, 2008, 18(4): 600-614.
[6] Zheng H, Kavanagh J J, Hu W, et al. Hormonal therapy in ovarian cancer. Int J Gynecol Cancer, 2007, 17(2): 325-338.
[7] 田丽媛, 赵亚力, 韩为东. 雌激素受体在卵巢癌发生发展中作用的研究进展. 国外医学妇产科学分册, 2007, 34(4): 254-257. Tian L Y, Zhao Y L, Han W D, et al. Advances in the role of estrogen receptor in ovarian carcinomas. J Inter Obstet Gynecol, 2007, 34(4): 254-257.
[8] Dobrzycka K M, Townson S M, Jiang S, et al. Estrogen receptor corepressors-a role in humann breast cancer? Endocrine-Related Cancer, 2003, 10(2): 517-536.
[9] 杨智洪, 王晓辉, 韩聚强, 等. 雌激素受体β共调节因子的研究进展. 生物技术通讯, 2006, 17(6): 935-938. Yang Z H, Wang X H, Han J Q, et al. Advances in estrogen receptor β coregulator. Lett Biotech, 17(6): 935-938.
[10] Lerch-Gaggl A, Haque J, Li J X, et al. Pescadillo is essential for nucleolar asse-mbly, ribosome biogenesis, and mammalian cell proliferation. J Biol Chem, 2002, 277(47): 45347-45355.
[11] Prisco M, Maiorana A, Guerzoni C, et al. Role of pescadillo and upstream bind-ing factor in the proliferation and differentiation of murine myeloid cells. Mol Cell Biol, 2004, 24(12):5421-5433.
[12] Maiorana1 A, Tu X, Cheng G J, et al. Role of pescadillo in the transformation and immortalization of mammalian cells. Oncogene, 2004, 23(42): 7116-7124.
[13] Byungsik K, Seunghyun B, Seungkoo L, et al. Expression profiling and subtype specific expression of stomach cancer. Cancer Res, 2003, 63(23): 8248-8255.
[14] Li Y W, Hong X, Hussain M, et al. Gene expression profiling revealed novel mo-lecular targets of docetaxel and estramustine combination treatment in prostate cancer cells. Mol Cancer Ther, 2005, 4(3): 389-398. |
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
| |
Shared |
|
|
|
|
| |
Discussed |
|
|
|
|
